



FOR IMMEDIATE RELEASE

Neuronetics Adds former CEO of VNUS Medical Technologies to Board of Directors

Malvern, PA [November 9, 2009] – Neuronetics today announced that Brian Farley, former President and Chief Executive Officer of VNUS Medical Technologies, Inc., was elected to Neuronetics' Board of Directors. Brian will serve as an independent director at Neuronetics.

At VNUS, Brian was the first employee at the company in 1995 and served as a member of the Board of Directors, President and Chief Executive Officer since January 1996. VNUS pioneered the concept of minimally invasive varicose vein ablation and was the leader in technology and market development. Brian and the VNUS team successfully built a profitable business of over \$100 million in annual revenues by focusing on clinical outcomes, reimbursement, and developing fast and easy to use products. VNUS underwent a successful IPO in 2004 and was acquired by Covidien for over \$500 million in June of 2009. Prior to July 1995, Mr. Farley was employed in various management and executive positions in research and development, clinical research and business development by Guidant Corporation, and in the medical device division of Eli Lilly & Company. Mr. Farley currently serves on the board of directors of Entellus, a privately held medical device company. Mr. Farley holds both a B.S. in Engineering with an emphasis in Biomedical Engineering and an M.S. in Electrical Engineering from Purdue University.

“Brian is a strong CEO and marketer who brings a diverse skill set to the Neuronetics Board. His experience with new market creation, guiding VNUS through the establishment of reimbursement, and leading the company to substantial sales success will be invaluable to us,” said Bruce Shook, Neuronetics' CEO. “Brian's experience as a successful public company CEO will also bring value to the Board.”

“Neuronetics' technology for the non-invasive treatment of depression is an exciting development for the millions of people in which medication treatment is not a solution,” said Brian Farley. “I'm very pleased to join the Neuronetics Board to assist the company as we move

to educate doctors, patients, and payers about the clinical merits of this new depression therapy.”

About Neuronetics

Neuronetics, Inc. is a privately-held medical device company focused on developing non-invasive therapies for psychiatric and neurological disorders using MRI-strength magnetic field pulses. Based in Malvern, PA, Neuronetics is the leader in the development of TMS Therapy, a non-invasive form of neuromodulation. For more information, please visit www.neuronetics.com.

About NeuroStar TMS Therapy

NeuroStar TMS Therapy was cleared by the FDA in October 2008 for patients who have not adequately benefitted from prior antidepressant medication*. NeuroStar TMS Therapy is a non-systemic (does not circulate in the bloodstream throughout the body) and non-invasive (does not involve surgery) form of neuromodulation. It stimulates nerve cells in an area of the brain that is linked to depression, by delivering highly focused MRI-strength magnetic field pulses. The treatment is typically administered daily for 4-6 weeks. In an open-label clinical trial, which is most like real world clinical practice, approximately 1 in 2 patients experienced significant improvement in symptoms, and 1 in 3 experienced complete symptom resolution. There were no systemic side effects, such as weight gain and sexual dysfunction. The most common adverse events related to treatment were scalp pain or discomfort at the treatment area during active TMS treatments. NeuroStar TMS Therapy is contraindicated in patients with metallic implants in or around the head. NeuroStar TMS Therapy may not be effective for all patients with depression and is available by prescription from a psychiatrist.

Availability of NeuroStar TMS Therapy

Treatment with NeuroStar TMS Therapy is or will soon be available at over 100 treatment centers in the US. For specific information on treatment locations with NeuroStar TMS Therapy, please visit www.NeuroStarTMS.com or call the Neuronetics Customer Service Center at (877) 600-7555.

About Depression

Depression affects at least 14 million American adults each year. Researchers estimate that by the year 2020, depression will be the second leading cause of disability worldwide. Each year,

over 30,000 people in the US commit suicide, 60% of which suffer from depression. The economic burden of depression in 2000 was estimated at \$83.1 billion in the US. Women are almost twice as likely as men to suffer from depression. However, some experts feel that depression in men is under-reported. Depression has no racial, ethnic, or socioeconomic boundaries. About two-thirds of those who experience an episode of depression will have at least one other episode in their lives. Despite major advances in treating this debilitating illness, nearly 30% of patients with depression do not benefit from or are intolerant of antidepressant therapy.

Media Contacts

Nancie Steinberg

Chamberlain Communications

Ph: 212-884-0667

E-mail: nsteinberg@chamberlainpr.com

NeuroStar TMS Therapy[®] is indicated for the treatment of Major Depressive Disorder in adult patients who have failed to achieve satisfactory improvement from one prior antidepressant medication at or above the minimal effective dose and duration in the current episode.

NeuroStar[®], NeuroStar TMS Therapy[®], and TMS Therapy[®] are registered trademarks of Neuronetics, Inc.